The estimated Net Worth of Frederick W Gluck is at least $2.02 Millón dollars as of 26 March 2018. Mr. Gluck owns over 5,000 units of CytomX Therapeutics Inc stock worth over $355,852 and over the last 21 years he sold CTMX stock worth over $1,523,450. In addition, he makes $136,497 as Independent Director at CytomX Therapeutics Inc.
Sign up
Mr. Gluck CTMX stock SEC Form 4 insiders trading
Frederick has made over 11 trades of the CytomX Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of CTMX stock worth $159,650 on 26 March 2018.
The largest trade he's ever made was exercising 93,124 units of CytomX Therapeutics Inc stock on 9 August 2016 worth over $118,267. On average, Frederick trades about 7,684 units every 26 days since 2004. As of 26 March 2018 he still owns at least 271,643 units of CytomX Therapeutics Inc stock.
You can see the complete history of Mr. Gluck stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Frederick Gluck biography
Frederick W. Gluck serves as Independent Director of the Company. He has served as a member of our Board since September 2010 and was a member of the board of directors of CytomX Therapeutics, LLC until September 2010. Mr. Gluck previously served as a member of the board of directors of Amgen, Inc. from February 1998 to October 2011. He has also served as founding chairman of the board and CEO of our predecessor company, CytomX, LLC, from 2006 to 2008. Mr. Gluck has served as a member of the board of Cynvenio Biosystems, Inc. (now LungLife AI), a private company that was spun off from CytomX in 2008, since 2008. He also served as co-chairman of the board of TrueVision Systems Inc. (“TrueVision”), a private company where he has served on the board from 2007 until 2018, when it was sold to Alcon. Mr. Gluck served as a consultant to McKinsey & Company, Inc., an international management-consulting firm (“McKinsey”), from July 1998 to July 2003. Prior to that, he was Vice Chairman and Director of Bechtel Group, Inc., an engineering, construction and project management company, from 1995 to July 1998. Mr. Gluck is a former partner of McKinsey, where he served from 1967 to 1995. Between 1988 and 1994, he led McKinsey as its global Managing Director. He also serves as a director of the Foundation Board of the University of California, Santa Barbara, the Kavli Institute of Theoretical Physics and The New York Presbyterian Hospital (Emeritus). Mr. Gluck has also served as the presiding director of the Hospital Corporation of America. Mr. Gluck received his B.S. from Manhattan College and M.S. from New York University in electrical engineering.
What is the salary of Frederick Gluck?
As the Independent Director of CytomX Therapeutics Inc, the total compensation of Frederick Gluck at CytomX Therapeutics Inc is $136,497. There are 11 executives at CytomX Therapeutics Inc getting paid more, with Sean McCarthy having the highest compensation of $3,769,930.
How old is Frederick Gluck?
Frederick Gluck is 84, he's been the Independent Director of CytomX Therapeutics Inc since 2010. There are 1 older and 17 younger executives at CytomX Therapeutics Inc. The oldest executive at CytomX Therapeutics Inc is Frederick W. Gluck, 86, who is the Co-Founder & Independent Director.
What's Frederick Gluck's mailing address?
Frederick's mailing address filed with the SEC is 743 SAN YSIDRO ROAD, , SANTA BARBARA, CA, 91308.
Insiders trading at CytomX Therapeutics Inc
Over the last 10 years, insiders at CytomX Therapeutics Inc have traded over $57,157,858 worth of CytomX Therapeutics Inc stock and bought 662,000 units worth $7,876,720 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Harbor Master Investors (Ca... y James E Deerfield Mgmt L.P..... On average, CytomX Therapeutics Inc executives and independent directors trade stock every 20 days with the average trade being worth of $48,707. The most recent stock trade was executed by Jeffrey B Landau on 20 August 2024, trading 11,250 units of CTMX stock currently worth $14,738.
What does CytomX Therapeutics Inc do?
cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
What does CytomX Therapeutics Inc's logo look like?
Complete history of Mr. Gluck stock trades at AMGEN y CytomX Therapeutics Inc
CytomX Therapeutics Inc executives and stock owners
CytomX Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Sean McCarthy,
Chairman of the Board, President, Chief Executive Officer -
Amy Peterson,
Executive Vice President, Chief Development Officer -
W. Michael Kavanaugh,
Senior Vice President, Chief Scientific Officer and Head - Research and Non-Clinical Development -
Lloyd Rowland,
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary -
Dr. Sean A. McCarthy D.Phil., DPHIL,
Chairman & CEO -
Dr. Amy C. Peterson M.D.,
Pres & COO -
Dr. Alison L. Hannah M.D.,
Sr. VP & Chief Medical Officer -
Lloyd A. Rowland Jr., J.D.,
Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec. -
Elaine Jones,
Independent Director -
Matthew Young,
Lead Independent Director -
John Scarlett,
Independent Director -
Frederick Gluck,
Independent Director -
James Meyers,
Independent Director -
Charles Fuchs,
Independent Director -
Frederick W. Gluck,
Co-Founder & Independent Director -
Alison Hannah,
Senior Vice President, Chief Medical Officer -
Halley Gilbert,
Independent Director -
Carlos Campoy,
Chief Financial Officer, Senior Vice President -
Christopher Keenan,
Vice President, Investor Relations and Corporate Communications -
Nick Galli,
Senior Vice President, Chief Business Officer -
Chris Ogden,
Interim Principal Accounting Officer and VP of Fin. & Accounting -
Leslie Robbins,
Sr. VP of Intellectual Property -
Alison Joly,
Sr. VP of Program & Alliance Management -
Danielle Olander,
Sr. VP, Talent & Systems Devel. -
Dr. Sridhar Viswanathan Ph.D.,
Sr. VP of Process Sciences & Manufacturing Operations -
Dr. Chau Cheng M.B.A., Ph.D.,
VP of Investor Relations & Corp. Communications -
Cynthia J Ladd,
Senior VP and General Counsel -
Marion Mc Court,
Director -
Rock Ventures Lp Third Rock...,
-
Neil Exter,
Director -
Rachel Humphrey,
Chief Medical Officer -
Ix L.P.Canaan Partners Ix L...,
-
Debanjan Ray,
Chief Financial Officer -
Hoyoung Huh,
Director -
Kevin P Starr,
10% owner -
Timothy M Shannon,
Director -
Ii Robert C. Goeltz,
Chief Financial Officer -
Zhen Su,
-
Robert I Tepper,
10% owner -
Partners L P/Ilbiotechnolog...,
-
Robin Knifsend,
Principal Accounting Officer -
James E Deerfield Mgmt L.P....,
-
Harbor Master Investors (Ca...,
10% owner -
Alan Ashworth,
-
Jeffrey B Landau,
Chief Business Officer -
Christopher Ogden,
Chief Financial Officer -
Marcia Belvin,
SVP, Chief Scientific Officer -
Yu Waye Chu,
Chief Medical Officer